Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Fitusiran prophylaxis shows encouraging results in hemophilia patients

Steven Pipe • 25 Nov 2020
ASH 2020
Hemophilia Fitusiran

Steven Pipe, MD, University of Michigan, Ann Arbor, MO, discusses the results of the Phase II, open-label extension study (NCT02554773) aiming to assess the long-term durability, efficacy and safety of fitusiran prophylaxis in hemophilia A or B (HA/HB) patients, with or without inhibitors. Fitusiran, a small interfering RNA, is designed to lower antithrombin level, thus improving thrombin generation and resulting in fewer and milder bleeds. In patients treated with fitusiran, the antithrombin blood levels were reported to fall below 20% of the norm. Monthly prophylaxis provided sustained antithrombin lowering in both HA and HB patients, with or without inhibitors, resulting in a low bleeding rate over the follow-up period. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consulting: Apcintex, Bayer, Biomarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics, uniQure

More from Steven Pipe

Primary analysis of HAVEN 7: emicizumab prophylaxis in infants with severe hemophilia A
8:37
Primary analysis of HAVEN 7: emicizumab prophylaxis in infants with severe hemophilia A
Steven Pipe • 11 Dec 2023
Updates from the HOPE-B trial: etranacogene dezaparvovec in adults with hemophilia B
8:50
Updates from the HOPE-B trial: etranacogene dezaparvovec in adults with hemophilia B
Steven Pipe • 12 Dec 2022
HAVEN 7: emicizumab prophylaxis for the treatment of infants with severe hemophilia A
6:11
HAVEN 7: emicizumab prophylaxis for the treatment of infants with severe hemophilia A
Steven Pipe • 12 Dec 2022
HOPE-B trial: etranacogene dezaparvovec shows promise in hemophilia B
3:49
HOPE-B trial: etranacogene dezaparvovec shows promise in hemophilia B
Steven Pipe • 25 Nov 2020

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals